Duyuru • Jan 07
Glow Lifetech Corp. Expands into Medical Cannabis Channel with National Launch on Mendo Glow Lifetech Corp. announced the launch of its MOD™? and .decimal™? product portfolio on the Mendo Medical Cannabis platform ("Mendo"), representing Glow's first formal entry into the Canadian medical cannabis channel and extending access to its products for registered medical patients nationwide. This launch represents an important milestone in Glow's commercial strategy, making its full portfolio (14 SKUs) of next-generation cannabis products available to medical patients across Canada, including veterans, who value greater consistency, dose-control, and personalization. Mendo Medical Cannabis is one of Canada's leading medical cannabis providers, serving registered patients across Canada, with a long-standing focus on veterans through dedicated support programs. Based in Quebec, Mendo operates a national online sales platform, providing both civilians and veterans with easy, secure access to high-quality cannabis products from Canada's top licensed producers. The addition of the medical channel further diversifies Glow's distribution mix heading into 2026 and reinforces the scalability of its business model. Alongside its growing presence with major provincial retailers, this expansion positions the Company to serve a broader customer base while maintaining focus on operational efficiency and long-term value creation. Duyuru • Jun 23
Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025 Glow Lifetech Corp., Annual General Meeting, Aug 28, 2025. Duyuru • Jun 03
Glow Lifetech Corp. Announces the Resignation of James Van Staveren from the Board of Directors Glow Lifetech Corp. announced that Mr. James Van Staveren has resigned from the Board of Directors of the Company, effective May 31, 2025. Duyuru • Jan 29
Glow Lifetech Corp. Announces Executive and Board Changes Glow LifeTech Corp. announced the appointment of David Ct as a new independent director to the Board of Directors (the "Board"), effective January 24, 2025. Mr. Ct is a seasoned leader in the cannabis retail industry, with extensive experience scaling retail operations and driving growth. David currently serves as Chief Executive Officer of J. Supply Holdings Inc., which owns the cannabis retail banners Northern Helm and J. Supply Co. Prior to this, David was Director of Retail Strategy at Canopy Growth Corporation, where he developed the model for franchising retail cannabis stores across Canada. These endeavours are built on a career in retail, leveraging learnings from the quick-service restaurant, consulting, and CPG industries to the cannabis space, having spent time at RBI, Accenture, and SC Johnson. David earned his MBA and HBA from the Ivey School of Business. The Company also wishes to announced that James Van Staveren has resigned from his position as a member of Glow's Audit Committee and as Corporate Secretary, effective January 24, 2025. Mr. Van Staveren will remain as a director on the Board. Glow would like to sincerely thank Mr. Van Staveren for his valuable services to the Company in his capacity as a member of Glow's Audit Committee and as Corporate Secretary. Effective January 24, 2025, Mr. Ct has been appointed to Glow's Audit Committee and Josh Bald, the Company's Chief Financial Officer, has been appointed as Corporate Secretary. Duyuru • Nov 06
Glow Lifetech Corp. announced that it expects to receive CAD 0.9 million in funding Glow Lifetech Corp. announced a non-brokered private placement that it will issue up to 18,000,000 units at an issue price of CAD 0.05 per unit for the gross proceeds of up to CAD 900,000 on November 5, 2024. Each Unit issued under the Offering will consist of one Share and one half of one common share purchase warrant. Each full Warrant will be exercisable to acquire one Share for a period of eighteen months following the closing of the Offering, at an exercise price of CAD 0.07 per Warrant Share. All securities issued in connection with the Offering will be subject to a four month and one day hold as required under applicable securities laws New Risk • Sep 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 113% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Negative equity (-CA$214k). Shareholders have been substantially diluted in the past year (113% increase in shares outstanding). Revenue is less than US$1m (CA$345k revenue, or US$255k). Market cap is less than US$10m (€4.42m market cap, or US$4.94m). Duyuru • Sep 25
Glow Lifetech Corp. announced that it has received CAD 1.2 million in funding On September 24,2024 Glow Lifetech Corp. closed the transaction. In connection with the Offering, the Company paid certain eligible persons: (i) cash commissions in the aggregate of CAD 2,400; and (ii) issued an aggregate of 80,000 finder warrants to such Finders. Each Finder Warrant is exercisable at a price of CAD 0.05 per Common Share until the date that is eighteen (18) months from the date of issuance. The Offering was approved by the members of the board of directors of the Company who are independent for the purposes of the Offering. Duyuru • Aug 14
Glow Lifetech Corp. announced that it expects to receive CAD 1.2 million in funding Glow Lifetech Corp announced a non-brokered private placement financing of up to 40,000,000 units at a price of CAD 0.03 per Unit for gross proceeds CAD 1,200,000 on August 14, 2024. Each Unit shall be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Warrant entitles the holder thereof to acquire one Common Share at a price of CAD 0.05 per Common Share for a period of eighteen months from the date of issuance. Closing of the Offering is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. Board Change • Aug 07
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 1 independent director (2 non-independent directors). CEO & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. Independent Director Daniel Proska was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Duyuru • Apr 17
Glow Lifetech Corp. announced that it expects to receive CAD 0.75 million in funding Glow Lifetech Corp. announced a non-brokered private placement financing of 25,000,000 units at issue price CAD 0.03 per unit for gross proceeds of CAD 750,000 on April 16, 2024. Each unit shall comprise one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of five cents per common share for a period of 18 months from the date of issuance. Closing of the offering is subject to receipt of all necessary corporate and regulatory approvals, including the approval of Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. New Risk • Feb 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average weekly change). Revenue is less than US$1m (CA$19k revenue, or US$14k). Market cap is less than US$10m (€1.27m market cap, or US$1.36m). Minor Risk Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Board Change • Jan 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Chief Commercial Officer & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Dec 17
Glow Lifetech Corp. announced that it expects to receive CAD 0.25 million in funding Glow Lifetech Corp. announced a non-brokered private placement of up to 5,000,000 units in the capital of the company at a price of CAD 0.05 per unit for the gross proceeds of up to CAD 250,000 on December 15, 2023. Each unit shall be comprised of one common share in the capital of the company and one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at a price of CAD 0.07 per common share for a period of 18 months from the date of issuance. The transaction is subject to receipt of all necessary corporate and regulatory approvals. All securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance and the resale rules of applicable securities legislation. Board Change • Nov 02
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Chief Commercial Officer & Director Rob Carducci is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Sep 08
Glow Lifetech Corp. Appoints Daniel Proska to Its Board of Directors Glow LifeTech Corp. announce the appointment of Daniel Proska as a new independent director to the Board of Directors, effective, September 6, 2023. With over 15 years of experience in senior sales and revenue growth roles across diverse sectors ranging from medical devices and robotics to software and cybersecurity Mr. Proska has demonstrated a unique capacity for driving business expansion. Notably, his contributions were pivotal in Venus Concepts' growth from $5 million to over $100 million in revenue, and supporting its growth to a NASDAQ listing. Proska's extensive experience in both commercial strategy and operating within regulated environments makes him an invaluable asset to Glow LifeTech. His familiarity with the regulatory complexities in industries such as medical devices and cybersecurity will complement his commercial and strategic acumen, further empowering the Company as it introduces its technology and products to Canada's tightly-regulated emerging cannabis market. Currently, Mr. Proska serves as the Chief Commercial Officer at Scryb Inc., an A.I. Platform that enables businesses across industries to create, enhance, and power disruptive solutions. Among the companies that have benefited from Scryb's capabilities is Cybeats Technologies Corp., a cybersecurity firm where Mr. Proska has contributed to the acquisition of Fortune 500 clients, affirming his capabilities to drive revenue growth and business outcomes. Chris Irwin will step down from his duties as a director of Glow, effective September 6, 2023. Duyuru • Jul 07
Glow Expands Technology Portfolio and Proprietary Product Format Capabilities; Develops New Water-Soluble Cannabis Powder Technology Glow LifeTech Corp. announce that it has developed a proprietary, water-soluble cannabis powder technology ("New Powder Technology''), which expands the Company's technology portfolio to both liquid and powder cannabinoid ingredients and unlocks a new range of product format capabilities. To protect the New Powder Technology, the Company has submitted provisional patent applications with the United States Patent and Trademark Office. The Company's New Powder Technology creates dry powder cannabinoids that are water-soluble and designed for improved absorption, great taste and a more consistent and predictable cannabis experience. Building on the Company's existing nature-based liquid MyCell® Technology, the New Powder Technology is uniquely made with only natural, plant-based ingredients, and cannabis extracts including THC, CBD, CBN and CBG distillates and isolates. The new powder ingredients expands Glow's growing portfolio of high-performance ingredients, and allows the Company to support a variety of new product formats including capsules, drink mixes, gummies, infused-foods, and more. The Company submitted provisional patent applications to the United States Patent and Trademark Office (USPTO) as part of its ongoing IP strategy for the powder technology. The filings allow Glow to ascribe the phrase "patent pending" to any commercial products, methods, or services contemplated by the subject matter claimed. The patent applications reflect Glow's strategy of strengthening its IP portfolio relating to cannabis and nutraceutical ingredient technologies. MyCell® Technology is Glow's proprietary delivery system that optimizes the absorption, bioavailability and effectiveness of natural active compounds including vitamins, cannabinoids and botanicals, using only 100% natural, food-grade components. It transforms poorly absorbed natural compounds into water-compatible concentrates that have fast-acting onset, high-absorption, precision dosing and a clean taste profile. With its portfolio of ingredients, Glow is powering a new era of more efficient, fast-acting, and great tasting functional foods, beverages, supplements, and personal care products. Duyuru • Dec 09
Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023 Glow Lifetech Corp., Annual General Meeting, Feb 22, 2023. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Technical Advisory Board Murray Berall was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Sep 17
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 